{
    "info": {
        "nct_id": "NCT06330064",
        "official_title": "A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)",
        "inclusion_criteria": "Participants must meet all of the following criteria to be included in the study:\n\nCommon Inclusion Criteria for All Participants\n\n1. Participant must have at least 1 lesion, not previously irradiated, amenable to core biopsy and must consent to provide a pretreatment biopsy tissue sample. An archival tumor tissue sample obtained within 6 months of consent and after progression during/after treatment with the participant's most recent cancer therapy regimen is also acceptable.\n2. Participants ages ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years).\n3. At least 1 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as assessed by the investigator.\n4. Documentation of radiological disease progression on or after the previous standard-of-care regimen in the advanced/metastatic setting.\n5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nAdditional Inclusion Criteria for EC Participants\n\n1. Pathologically or cytologically documented EC of any histological carcinoma subtype or endometrial carcinosarcoma, irrespective of microsatellite instability or mismatch repair status.\n2. Relapse or progression after a platinum-containing systemic treatment and an immune checkpoint inhibitor (ICI)-containing regimen (combined or sequential). Subjects with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma. Neoadjuvant/adjuvant therapy may count as 1 line of therapy if the subject progressed within 6 months after completion of therapy.\n\nAdditional Inclusion Criteria for HNSCC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, excluding nasopharynx, nasal cavity and paranasal sinuses, and unknown primary.\n2. Has disease progression after platinum-based and ICI treatment, whether administered in combination or separately. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 2 prior therapy lines for unresectable or metastatic HNSCC.\n3. Participants without radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrating a >90-degree abutment or encasement of a major blood vessel.\n4. Participants with no prior history of Grade ≥3 bleeding as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 within 28 days prior to the start of study drug related to the current head and neck cancer may be included in the study.\n5. Documented p16 status for oropharyngeal cancer (historical results are acceptable if available).\n\nAdditional Inclusion Criterion for PDAC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma that has relapsed or progressed after 1 prior line of gemcitabine-based systemic therapy in the locally advanced/metastatic setting or after 2 lines of therapy if the subject has actionable target tumor mutation and has been previously treated with targeted therapy. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.\n\nAdditional Inclusion Criteria for CRC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic CRC with microsatellite stable status.\n2. Relapse or progression after 1 prior line of systemic therapy including a fluoropyrimidine plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated, or relapse or progression after 2 lines of therapy if the subject has received targeted therapy.\n\n   Note: Prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy will count as 1 line of prior systemic therapy if there is documented disease progression during therapy or within 6 months of chemotherapy completion.\n3. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.\n\nAdditional Inclusion Criteria for HCC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) or noninvasive diagnosis of HCC as per the American Association for the Study of Liver Diseases (AASLD) criteria in subjects with a confirmed diagnosis of cirrhosis.\n2. Relapse or progression after 1 prior line of an ICI-containing regimen (combination or monotherapy) in the locally advanced/metastatic setting, with a maximum of 2 prior lines. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.\n3. Barcelona Clinic Liver Cancer (BCLC) Stage B or C.\n4. Liver function status should be Child-Pugh (CP) Class A.\n5. Albumin-Bilirubin (ALBI) Grade 1 within 7 days prior to the first dose of study drug.\n6. Participants with large esophageal varices at risk of bleeding must be treated with conventional medical intervention: beta blockers or endoscopic treatment.\n\nAdditional Inclusion Criteria for Ad-eso/GEJ/Gastric Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic Ad-eso/GEJ/Gastric that has relapsed or progressed after 1 prior line of systemic therapy in the locally advanced/metastatic setting. Subjects with PD-(L)1+ or MSI-H/dMMR should receive ICI treatment if ICIs are standard of care in the country, unless the subject is ineligible for ICI treatment.\n2. If the participant has known history of HER2 positivity (defined by IHC 3+ or IHC 2+ and in situ hybridization [ISH] positive, as classified by American Society of Clinical Oncology - College of American Pathologists [ASCO CAP]) or actionable target, the subject must have been previously treated with a targeted therapy.\n\nAdditional Inclusion Criteria for UC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra. Participants with histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology.\n2. Relapse or progression after at least 1 prior line of ICI-containing systemic therapy, and 1 prior line of systemic chemotherapy, given in combination with other anticancer therapy or separately, with a maximum of 3 prior therapy lines.\n\n   1. At least 1 line of therapy should include enfortumab vedotin in countries where enfortumab vedotin is approved and available.\n   2. Perioperative systemic therapies will be counted as 1 line of therapy.\n   3. To meet inclusion criteria requirement of prior ICI-containing therapy, use in the perioperative or metastatic setting will suffice.\n   4. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.\n   5. The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy.\n\nAdditional Inclusion Criteria for CC Participants\n\n1. Histologically confirmed unresectable or metastatic CC that was previously treated with ≥1 prior line of systemic therapy in the locally advanced or metastatic setting. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.\n2. Participants should receive prior anti-programmed death 1/programmed death-ligand 1 treatment and/or tisotumab vedotin if those are standard of care in the country, unless the subject is ineligible for these treatments.\n\nAdditional Inclusion Criteria for OVC Participants\n\n1. Histologically confirmed high-grade serous OVC, high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer that was previously treated with at least 1 line of platinum-based therapy and bevacizumab unless the subject is ineligible for treatment with bevacizumab.\n2. Participant is no longer considered eligible for platinum-based therapy per the investigator's opinion or has progressed less than 180 days after the last dose of platinum therapy.\n3. Participant is not considered primary platinum refractory and has not progressed during platinum treatment or within 4 weeks after the completion of platinum treatment.\n4. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.\n\nAdditional Inclusion Criteria for BTC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic BTC (intra- or extrahepatic cholangiocarcinoma or gallbladder carcinoma).\n2. Relapse or progression after at least 1 prior line of systemic therapy, or 2 prior lines of systemic therapy if the participant has an actionable target and has received targeted therapy.\n3. Histological subtypes other than ampullary cancer, small cell cancer, lymphoma, sarcoma, neuroendocrine tumors, mixed tumor histology, and/or mucinous cystic neoplasms (Please note that the histological subtypes listed here are not allowed.)\n\nAdditional Inclusion Criteria for HER2-Low BC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic BC.\n2. Low HER2 expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested), according to ASCO-CAP 2018 HER2 testing guidelines, based on most recent testing, regardless of hormonal status.\n3. Progression on or after treatment with trastuzumab deruxtecan (T-DXd).\n4. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Subjects with metastatic hormone receptor (HR)+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.\n\nAdditional Inclusion Criteria for HER2 IHC 0 BC Participants\n\n1. Pathologically or cytologically documented unresectable or metastatic BC.\n2. Negative for HER2 expression, defined as IHC 0 (ISH- or untested) according to ASCO-CAP 2018 HER2 testing guidelines, based on the most recent testing, regardless of hormonal status.\n3. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Participants with metastatic HR+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.\n\nAdditional Inclusion Criteria for Cutaneous (Acral and Non-acral) Melanoma Subjects\n\n1. Histologically or cytologically confirmed cutaneous (acral and non-acral) melanoma.\n2. Disease progression while on or after having received treatment with ≥1 prior line of ICI based therapy. Prior anti-PD-(L)1 therapy in the adjuvant setting may be counted as 1 line if there is recurrence within 12 weeks of the last dose. If the subject had BRAF mutated melanoma or other actionable target tumor mutation, they must have had disease progression on targeted therapy as well.\n\nParticipants who meet any of the following criteria will be disqualified from entering the study:\n\n1. Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd.\n2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, T-DXd) due to treatment-related toxicities.\n3. Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.\n4. Inadequate treatment washout period before enrollment as specified in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Additional Inclusion Criteria for Ad-eso/GEJ/Gastric Participants",
            "criterions": [
                {
                    "exact_snippets": "Ad-eso/GEJ/Gastric Participants",
                    "criterion": "cancer type/location",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "adenocarcinoma of the esophagus",
                                "gastroesophageal junction (GEJ)",
                                "gastric (stomach)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Histological subtypes other than ampullary cancer, small cell cancer, lymphoma, sarcoma, neuroendocrine tumors, mixed tumor histology, and/or mucinous cystic neoplasms (Please note that the histological subtypes listed here are not allowed.)",
            "criterions": [
                {
                    "exact_snippets": "Histological subtypes other than ampullary cancer, small cell cancer, lymphoma, sarcoma, neuroendocrine tumors, mixed tumor histology, and/or mucinous cystic neoplasms (Please note that the histological subtypes listed here are not allowed.)",
                    "criterion": "histological subtype",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "ampullary cancer",
                                "small cell cancer",
                                "lymphoma",
                                "sarcoma",
                                "neuroendocrine tumors",
                                "mixed tumor histology",
                                "mucinous cystic neoplasms"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Participants with large esophageal varices at risk of bleeding must be treated with conventional medical intervention: beta blockers or endoscopic treatment.",
            "criterions": [
                {
                    "exact_snippets": "large esophageal varices at risk of bleeding",
                    "criterion": "esophageal varices",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": "large"
                        },
                        {
                            "requirement_type": "risk of bleeding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be treated with conventional medical intervention: beta blockers or endoscopic treatment",
                    "criterion": "treatment for esophageal varices at risk of bleeding",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "beta blockers",
                                "endoscopic treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Relapse or progression after at least 1 prior line of systemic therapy, or 2 prior lines of systemic therapy if the participant has an actionable target and has received targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Relapse or progression after at least 1 prior line of systemic therapy",
                    "criterion": "relapse or progression after prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of systemic therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "2 prior lines of systemic therapy if the participant has an actionable target and has received targeted therapy",
                    "criterion": "relapse or progression after prior systemic therapy with actionable target and targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of systemic therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "actionable target",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "received targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic BTC (intra- or extrahepatic cholangiocarcinoma or gallbladder carcinoma).",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented",
                    "criterion": "BTC diagnosis documentation",
                    "requirements": [
                        {
                            "requirement_type": "documentation method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable or metastatic BTC",
                    "criterion": "BTC disease status",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "intra- or extrahepatic cholangiocarcinoma or gallbladder carcinoma",
                    "criterion": "BTC subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "intrahepatic cholangiocarcinoma",
                                "extrahepatic cholangiocarcinoma",
                                "gallbladder carcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. At least 1 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as assessed by the investigator.",
            "criterions": [
                {
                    "exact_snippets": "At least 1 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        },
                        {
                            "requirement_type": "assessment criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. If the participant has known history of HER2 positivity (defined by IHC 3+ or IHC 2+ and in situ hybridization [ISH] positive, as classified by American Society of Clinical Oncology - College of American Pathologists [ASCO CAP]) or actionable target, the subject must have been previously treated with a targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "known history of HER2 positivity (defined by IHC 3+ or IHC 2+ and in situ hybridization [ISH] positive, as classified by American Society of Clinical Oncology - College of American Pathologists [ASCO CAP])",
                    "criterion": "HER2 positivity",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": [
                                "IHC 3+",
                                "IHC 2+ and in situ hybridization [ISH] positive"
                            ]
                        },
                        {
                            "requirement_type": "classification_system",
                            "expected_value": "ASCO CAP"
                        }
                    ]
                },
                {
                    "exact_snippets": "actionable target",
                    "criterion": "actionable target",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the subject must have been previously treated with a targeted therapy",
                    "criterion": "prior targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participants with no prior history of Grade ≥3 bleeding as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 within 28 days prior to the start of study drug related to the current head and neck cancer may be included in the study.",
            "criterions": [
                {
                    "exact_snippets": "no prior history of Grade ≥3 bleeding as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 within 28 days prior to the start of study drug related to the current head and neck cancer",
                    "criterion": "bleeding events related to current head and neck cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NCI-CTCAE v5.0 grade"
                            }
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to start of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Has disease progression after platinum-based and ICI treatment, whether administered in combination or separately. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 2 prior therapy lines for unresectable or metastatic HNSCC.",
            "criterions": [
                {
                    "exact_snippets": "Has disease progression after platinum-based and ICI treatment, whether administered in combination or separately.",
                    "criterion": "disease progression after platinum-based and ICI treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of disease progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": [
                                "platinum-based",
                                "ICI"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation should have been previously treated with targeted therapy",
                    "criterion": "actionable target tumor mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior treatment with targeted therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a maximum of 2 prior therapy lines for unresectable or metastatic HNSCC",
                    "criterion": "number of prior therapy lines for unresectable or metastatic HNSCC",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapy lines",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation",
                    "criterion": "actionable target tumor mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should have been previously treated with targeted therapy",
                    "criterion": "prior targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Inclusion Criteria for BTC Participants",
            "criterions": [
                {
                    "exact_snippets": "BTC Participants",
                    "criterion": "BTC participants",
                    "requirements": [
                        {
                            "requirement_type": "disease type",
                            "expected_value": "BTC (biliary tract cancer)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Inclusion Criteria for HER2-Low BC Participants",
            "criterions": [
                {
                    "exact_snippets": "HER2-Low BC Participants",
                    "criterion": "HER2-Low breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "HER2-Low breast cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, T-DXd) due to treatment-related toxicities.",
            "criterions": [
                {
                    "exact_snippets": "Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, T-DXd) due to treatment-related toxicities.",
                    "criterion": "prior discontinuation of exatecan derivative ADC",
                    "requirements": [
                        {
                            "requirement_type": "history of discontinuation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "reason for discontinuation",
                            "expected_value": "treatment-related toxicities"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Perioperative systemic therapies will be counted as 1 line of therapy.",
            "criterions": [
                {
                    "exact_snippets": "Perioperative systemic therapies will be counted as 1 line of therapy.",
                    "criterion": "perioperative systemic therapies",
                    "requirements": [
                        {
                            "requirement_type": "line of therapy count",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Relapse or progression after at least 1 prior line of ICI-containing systemic therapy, and 1 prior line of systemic chemotherapy, given in combination with other anticancer therapy or separately, with a maximum of 3 prior therapy lines.",
            "criterions": [
                {
                    "exact_snippets": "Relapse or progression after at least 1 prior line of ICI-containing systemic therapy",
                    "criterion": "relapse or progression after ICI-containing systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of relapse or progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior ICI-containing systemic therapy lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "1 prior line of systemic chemotherapy, given in combination with other anticancer therapy or separately",
                    "criterion": "prior systemic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior systemic chemotherapy lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum of 3 prior therapy lines",
                    "criterion": "total number of prior therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapy lines",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) or noninvasive diagnosis of HCC as per the American Association for the Study of Liver Diseases (AASLD) criteria in subjects with a confirmed diagnosis of cirrhosis.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented unresectable or metastatic HCC",
                    "criterion": "hepatocellular carcinoma (HCC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible",
                    "criterion": "HCC subtype",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "fibrolamellar",
                                "mixed hepatocellular/cholangiocarcinoma"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "noninvasive diagnosis of HCC as per the American Association for the Study of Liver Diseases (AASLD) criteria in subjects with a confirmed diagnosis of cirrhosis",
                    "criterion": "hepatocellular carcinoma (HCC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis method",
                            "expected_value": "noninvasive (AASLD criteria)"
                        },
                        {
                            "requirement_type": "cirrhosis diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic Ad-eso/GEJ/Gastric that has relapsed or progressed after 1 prior line of systemic therapy in the locally advanced/metastatic setting. Subjects with PD-(L)1+ or MSI-H/dMMR should receive ICI treatment if ICIs are standard of care in the country, unless the subject is ineligible for ICI treatment.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented",
                    "criterion": "diagnosis documentation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable or metastatic Ad-eso/GEJ/Gastric",
                    "criterion": "disease status and type",
                    "requirements": [
                        {
                            "requirement_type": "disease_type",
                            "expected_value": [
                                "adenocarcinoma of esophagus (Ad-eso)",
                                "gastroesophageal junction (GEJ)",
                                "gastric"
                            ]
                        },
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has relapsed or progressed after 1 prior line of systemic therapy in the locally advanced/metastatic setting",
                    "criterion": "prior systemic therapy and disease progression",
                    "requirements": [
                        {
                            "requirement_type": "prior_lines_of_therapy",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "line"
                            }
                        },
                        {
                            "requirement_type": "setting",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "disease_status_post_therapy",
                            "expected_value": [
                                "relapsed",
                                "progressed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with PD-(L)1+ or MSI-H/dMMR should receive ICI treatment if ICIs are standard of care in the country, unless the subject is ineligible for ICI treatment.",
                    "criterion": "biomarker status and prior ICI treatment",
                    "requirements": [
                        {
                            "requirement_type": "biomarker_status",
                            "expected_value": [
                                "PD-(L)1 positive",
                                "MSI-H",
                                "dMMR"
                            ]
                        },
                        {
                            "requirement_type": "prior_ICI_treatment_if_standard_of_care",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ICI_ineligibility_exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy.",
            "criterions": [
                {
                    "exact_snippets": "The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy.",
                    "criterion": "counting of prior therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "counting method",
                            "expected_value": "the same regimen administered twice in different disease settings is counted as 1 line"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation",
                    "criterion": "actionable target tumor mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should have been previously treated with targeted therapy",
                    "criterion": "prior targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Negative for HER2 expression, defined as IHC 0 (ISH- or untested) according to ASCO-CAP 2018 HER2 testing guidelines, based on the most recent testing, regardless of hormonal status.",
            "criterions": [
                {
                    "exact_snippets": "Negative for HER2 expression, defined as IHC 0 (ISH- or untested) according to ASCO-CAP 2018 HER2 testing guidelines, based on the most recent testing",
                    "criterion": "HER2 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "IHC score",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "ISH status",
                            "expected_value": [
                                "negative",
                                "untested"
                            ]
                        },
                        {
                            "requirement_type": "testing guidelines",
                            "expected_value": "ASCO-CAP 2018 HER2 testing guidelines"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": "most recent testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants should receive prior anti-programmed death 1/programmed death-ligand 1 treatment and/or tisotumab vedotin if those are standard of care in the country, unless the subject is ineligible for these treatments.",
            "criterions": [
                {
                    "exact_snippets": "Participants should receive prior anti-programmed death 1/programmed death-ligand 1 treatment and/or tisotumab vedotin if those are standard of care in the country",
                    "criterion": "prior anti-programmed death 1/programmed death-ligand 1 treatment and/or tisotumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "standard of care in the country",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the subject is ineligible for these treatments",
                    "criterion": "eligibility for anti-programmed death 1/programmed death-ligand 1 treatment and/or tisotumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Barcelona Clinic Liver Cancer (BCLC) Stage B or C.",
            "criterions": [
                {
                    "exact_snippets": "Barcelona Clinic Liver Cancer (BCLC) Stage B or C",
                    "criterion": "Barcelona Clinic Liver Cancer (BCLC) stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Documentation of radiological disease progression on or after the previous standard-of-care regimen in the advanced/metastatic setting.",
            "criterions": [
                {
                    "exact_snippets": "Documentation of radiological disease progression",
                    "criterion": "radiological disease progression",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. To meet inclusion criteria requirement of prior ICI-containing therapy, use in the perioperative or metastatic setting will suffice.",
            "criterions": [
                {
                    "exact_snippets": "prior ICI-containing therapy",
                    "criterion": "prior ICI-containing therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "use in the perioperative or metastatic setting will suffice",
                    "criterion": "setting of ICI-containing therapy",
                    "requirements": [
                        {
                            "requirement_type": "setting",
                            "expected_value": [
                                "perioperative",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic BC.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented",
                    "criterion": "breast cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable or metastatic BC",
                    "criterion": "breast cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic BC.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented",
                    "criterion": "breast cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable or metastatic BC",
                    "criterion": "breast cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. At least 1 line of therapy should include enfortumab vedotin in countries where enfortumab vedotin is approved and available.",
            "criterions": [
                {
                    "exact_snippets": "At least 1 line of therapy should include enfortumab vedotin",
                    "criterion": "line of therapy including enfortumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        },
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "enfortumab vedotin"
                        }
                    ]
                },
                {
                    "exact_snippets": "in countries where enfortumab vedotin is approved and available",
                    "criterion": "country approval and availability of enfortumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "approval_status",
                            "expected_value": "approved"
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Subjects with metastatic hormone receptor (HR)+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy",
                    "criterion": "relapse or progression after prior lines of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of systemic therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "relapse or progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic hormone receptor (HR)+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting",
                    "criterion": "metastatic hormone receptor positive breast cancer with prior endocrine-based therapy and prior lines of additional systemic therapy in metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "disease type",
                            "expected_value": "metastatic hormone receptor positive breast cancer"
                        },
                        {
                            "requirement_type": "prior endocrine-based therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior lines of additional systemic therapy in metastatic setting",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation should have been previously treated with targeted therapy",
                    "criterion": "actionable target tumor mutation with prior targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "actionable target tumor mutation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd.",
                    "criterion": "prior treatment with orlotamab",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd.",
                    "criterion": "prior treatment with enoblituzumab",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd.",
                    "criterion": "prior treatment with B7-homologue 3 (B7-H3)-targeted agents",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd.",
                    "criterion": "prior treatment with I-DXd",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Relapse or progression after a platinum-containing systemic treatment and an immune checkpoint inhibitor (ICI)-containing regimen (combined or sequential). Subjects with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma. Neoadjuvant/adjuvant therapy may count as 1 line of therapy if the subject progressed within 6 months after completion of therapy.",
            "criterions": [
                {
                    "exact_snippets": "Relapse or progression after a platinum-containing systemic treatment",
                    "criterion": "relapse or progression after platinum-containing systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of relapse or progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior treatment type",
                            "expected_value": "platinum-containing systemic treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Relapse or progression after ... an immune checkpoint inhibitor (ICI)-containing regimen (combined or sequential)",
                    "criterion": "relapse or progression after immune checkpoint inhibitor-containing regimen",
                    "requirements": [
                        {
                            "requirement_type": "history of relapse or progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior treatment type",
                            "expected_value": "immune checkpoint inhibitor-containing regimen"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation should have been previously treated with targeted therapy",
                    "criterion": "prior targeted therapy for actionable target tumor mutation",
                    "requirements": [
                        {
                            "requirement_type": "actionable target tumor mutation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior treatment type",
                            "expected_value": "targeted therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum of 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma",
                    "criterion": "number of prior lines of therapy for endometrial carcinoma or carcinosarcoma",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Neoadjuvant/adjuvant therapy may count as 1 line of therapy if the subject progressed within 6 months after completion of therapy",
                    "criterion": "progression within 6 months after neoadjuvant/adjuvant therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after neoadjuvant/adjuvant therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time to progression after therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.",
            "criterions": [
                {
                    "exact_snippets": "No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.",
                    "criterion": "prior treatment with topoisomerase I inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma that has relapsed or progressed after 1 prior line of gemcitabine-based systemic therapy in the locally advanced/metastatic setting or after 2 lines of therapy if the subject has actionable target tumor mutation and has been previously treated with targeted therapy. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented",
                    "criterion": "pancreatic adenocarcinoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable or metastatic pancreatic adenocarcinoma",
                    "criterion": "pancreatic adenocarcinoma stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has relapsed or progressed after 1 prior line of gemcitabine-based systemic therapy in the locally advanced/metastatic setting",
                    "criterion": "prior gemcitabine-based systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number_of_prior_lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "setting",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "relapsed_or_progressed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "after 2 lines of therapy if the subject has actionable target tumor mutation and has been previously treated with targeted therapy",
                    "criterion": "prior lines of therapy with actionable mutation and targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "number_of_prior_lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "actionable_target_tumor_mutation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior_targeted_therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan",
                    "criterion": "prior topoisomerase I inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior_treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra. Participants with histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra.",
                    "criterion": "urothelial carcinoma (UC) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "pathologically documented",
                                "cytologically documented"
                            ]
                        },
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "primary_site",
                            "expected_value": [
                                "bladder",
                                "renal pelvis",
                                "ureter",
                                "urethra"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with histological variants are allowed if urothelial histology is predominant.",
                    "criterion": "histological variant",
                    "requirements": [
                        {
                            "requirement_type": "predominant_histology",
                            "expected_value": "urothelial"
                        }
                    ]
                },
                {
                    "exact_snippets": "Small cell/neuroendocrine tumors are not allowed even if mixed histology.",
                    "criterion": "small cell/neuroendocrine tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Liver function status should be Child-Pugh (CP) Class A.",
            "criterions": [
                {
                    "exact_snippets": "Liver function status should be Child-Pugh (CP) Class A.",
                    "criterion": "liver function status",
                    "requirements": [
                        {
                            "requirement_type": "Child-Pugh class",
                            "expected_value": "A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Inclusion Criteria for Cutaneous (Acral and Non-acral) Melanoma Subjects",
            "criterions": [
                {
                    "exact_snippets": "Cutaneous (Acral and Non-acral) Melanoma Subjects",
                    "criterion": "cutaneous melanoma subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "acral",
                                "non-acral"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Inclusion Criteria for HER2 IHC 0 BC Participants",
            "criterions": [
                {
                    "exact_snippets": "HER2 IHC 0 BC Participants",
                    "criterion": "HER2 IHC status",
                    "requirements": [
                        {
                            "requirement_type": "immunohistochemistry (IHC) score",
                            "expected_value": "0"
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2 IHC 0 BC Participants",
                    "criterion": "breast cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically or cytologically confirmed cutaneous (acral and non-acral) melanoma.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "melanoma diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cutaneous (acral and non-acral) melanoma",
                    "criterion": "melanoma type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "cutaneous",
                                "acral",
                                "non-acral"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically confirmed unresectable or metastatic CC that was previously treated with ≥1 prior line of systemic therapy in the locally advanced or metastatic setting. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed unresectable or metastatic CC",
                    "criterion": "cholangiocarcinoma (CC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable or metastatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with ≥1 prior line of systemic therapy in the locally advanced or metastatic setting",
                    "criterion": "systemic therapy lines in locally advanced or metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "setting",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation should have been previously treated with targeted therapy",
                    "criterion": "actionable target tumor mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants ages ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years).",
            "criterions": [
                {
                    "exact_snippets": "Participants ages ≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "follow local regulatory requirements if the legal age of consent for study participation is >18 years",
                    "criterion": "legal age of consent for study participation",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": "follow local regulatory requirements if >18 years"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Albumin-Bilirubin (ALBI) Grade 1 within 7 days prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Albumin-Bilirubin (ALBI) Grade 1 within 7 days prior to the first dose of study drug.",
                    "criterion": "Albumin-Bilirubin (ALBI) grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "1"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to the first dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participant is not considered primary platinum refractory and has not progressed during platinum treatment or within 4 weeks after the completion of platinum treatment.",
            "criterions": [
                {
                    "exact_snippets": "Participant is not considered primary platinum refractory",
                    "criterion": "primary platinum refractory status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "has not progressed during platinum treatment or within 4 weeks after the completion of platinum treatment",
                    "criterion": "disease progression during or shortly after platinum treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression during platinum treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "progression within 4 weeks after completion of platinum treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participants without radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrating a >90-degree abutment or encasement of a major blood vessel.",
            "criterions": [
                {
                    "exact_snippets": "without radiographic evidence of major blood vessel invasion/infiltration",
                    "criterion": "major blood vessel invasion/infiltration",
                    "requirements": [
                        {
                            "requirement_type": "radiographic evidence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor demonstrating a >90-degree abutment or encasement of a major blood vessel",
                    "criterion": "tumor abutment or encasement of a major blood vessel",
                    "requirements": [
                        {
                            "requirement_type": "degree of abutment or encasement",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "degree"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, excluding nasopharynx, nasal cavity and paranasal sinuses, and unknown primary.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented",
                    "criterion": "diagnosis documentation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable or metastatic squamous cell carcinoma",
                    "criterion": "squamous cell carcinoma status",
                    "requirements": [
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx",
                    "criterion": "primary tumor location",
                    "requirements": [
                        {
                            "requirement_type": "anatomic_site",
                            "expected_value": [
                                "oral cavity",
                                "oropharynx",
                                "hypopharynx",
                                "larynx"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding nasopharynx, nasal cavity and paranasal sinuses, and unknown primary",
                    "criterion": "excluded tumor locations",
                    "requirements": [
                        {
                            "requirement_type": "excluded_sites",
                            "expected_value": [
                                "nasopharynx",
                                "nasal cavity",
                                "paranasal sinuses",
                                "unknown primary"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Participants with metastatic HR+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy",
                    "criterion": "relapse or progression after prior lines of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of systemic therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with metastatic HR+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting",
                    "criterion": "metastatic HR+ breast cancer with prior endocrine-based therapy and prior lines of additional systemic therapy in metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "metastatic HR+ breast cancer"
                        },
                        {
                            "requirement_type": "prior endocrine-based therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior lines of additional systemic therapy in metastatic setting",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation should have been previously treated with targeted therapy",
                    "criterion": "actionable target tumor mutation and prior targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence of actionable target tumor mutation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Documented p16 status for oropharyngeal cancer (historical results are acceptable if available).",
            "criterions": [
                {
                    "exact_snippets": "Documented p16 status for oropharyngeal cancer (historical results are acceptable if available)",
                    "criterion": "p16 status",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented EC of any histological carcinoma subtype or endometrial carcinosarcoma, irrespective of microsatellite instability or mismatch repair status.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented EC of any histological carcinoma subtype or endometrial carcinosarcoma",
                    "criterion": "endometrial cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation",
                            "expected_value": [
                                "pathologically documented",
                                "cytologically documented"
                            ]
                        },
                        {
                            "requirement_type": "histological subtype",
                            "expected_value": "any carcinoma subtype or endometrial carcinosarcoma"
                        }
                    ]
                },
                {
                    "exact_snippets": "irrespective of microsatellite instability or mismatch repair status",
                    "criterion": "microsatellite instability or mismatch repair status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "any"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically or cytologically documented unresectable or metastatic CRC with microsatellite stable status.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically or cytologically documented",
                    "criterion": "colorectal cancer (CRC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable or metastatic CRC",
                    "criterion": "colorectal cancer (CRC)",
                    "requirements": [
                        {
                            "requirement_type": "disease_stage",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "microsatellite stable status",
                    "criterion": "microsatellite status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Low HER2 expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested), according to ASCO-CAP 2018 HER2 testing guidelines, based on most recent testing, regardless of hormonal status.",
            "criterions": [
                {
                    "exact_snippets": "Low HER2 expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested), according to ASCO-CAP 2018 HER2 testing guidelines, based on most recent testing",
                    "criterion": "HER2 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression level",
                            "expected_value": [
                                "IHC 2+/ISH-",
                                "IHC 1+/ISH-",
                                "IHC 1+/untested"
                            ]
                        },
                        {
                            "requirement_type": "testing guidelines",
                            "expected_value": "ASCO-CAP 2018 HER2 testing guidelines"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": "most recent testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically confirmed high-grade serous OVC, high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer that was previously treated with at least 1 line of platinum-based therapy and bevacizumab unless the subject is ineligible for treatment with bevacizumab.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed high-grade serous OVC",
                    "criterion": "high-grade serous ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "high-grade endometrioid OVC",
                    "criterion": "high-grade endometrioid ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "primary peritoneal cancer",
                    "criterion": "primary peritoneal cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fallopian tube cancer",
                    "criterion": "fallopian tube cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with at least 1 line of platinum-based therapy",
                    "criterion": "prior platinum-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with ... bevacizumab unless the subject is ineligible for treatment with bevacizumab",
                    "criterion": "prior bevacizumab therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception if ineligible for bevacizumab",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.",
            "criterions": [
                {
                    "exact_snippets": "Clinically active brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "clinically active"
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal cord compression",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal carcinomatosis",
                    "criterion": "leptomeningeal carcinomatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated or symptomatic",
                    "criterion": "CNS disease (brain metastases, spinal cord compression, or leptomeningeal carcinomatosis)",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring therapy with steroids or anticonvulsants to control associated symptoms",
                    "criterion": "CNS disease (brain metastases, spinal cord compression, or leptomeningeal carcinomatosis)",
                    "requirements": [
                        {
                            "requirement_type": "requirement for therapy",
                            "expected_value": [
                                "steroids",
                                "anticonvulsants"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Relapse or progression after 1 prior line of systemic therapy including a fluoropyrimidine plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated, or relapse or progression after 2 lines of therapy if the subject has received targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Relapse or progression after 1 prior line of systemic therapy including a fluoropyrimidine plus oxaliplatin",
                    "criterion": "relapse or progression after prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "prior therapy regimen",
                            "expected_value": [
                                "fluoropyrimidine",
                                "oxaliplatin"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated",
                    "criterion": "prior anti-VEGF or anti-EGFR mAb therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": [
                                "anti-VEGF mAb",
                                "anti-EGFR mAb",
                                "not required"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "relapse or progression after 2 lines of therapy if the subject has received targeted therapy",
                    "criterion": "relapse or progression after prior lines of therapy with targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": "targeted therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant must have at least 1 lesion, not previously irradiated, amenable to core biopsy and must consent to provide a pretreatment biopsy tissue sample. An archival tumor tissue sample obtained within 6 months of consent and after progression during/after treatment with the participant's most recent cancer therapy regimen is also acceptable.",
            "criterions": [
                {
                    "exact_snippets": "Participant must have at least 1 lesion",
                    "criterion": "number of lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously irradiated",
                    "criterion": "lesion irradiation status",
                    "requirements": [
                        {
                            "requirement_type": "irradiation status",
                            "expected_value": "not previously irradiated"
                        }
                    ]
                },
                {
                    "exact_snippets": "amenable to core biopsy",
                    "criterion": "lesion amenability to core biopsy",
                    "requirements": [
                        {
                            "requirement_type": "amenability to core biopsy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must consent to provide a pretreatment biopsy tissue sample",
                    "criterion": "consent to provide pretreatment biopsy tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "An archival tumor tissue sample obtained within 6 months of consent and after progression during/after treatment with the participant's most recent cancer therapy regimen is also acceptable",
                    "criterion": "archival tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "obtained within months of consent",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "obtained after progression during/after most recent cancer therapy regimen",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Progression on or after treatment with trastuzumab deruxtecan (T-DXd).",
            "criterions": [
                {
                    "exact_snippets": "Progression on or after treatment with trastuzumab deruxtecan (T-DXd)",
                    "criterion": "disease progression after trastuzumab deruxtecan (T-DXd) treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression_status",
                            "expected_value": "progression"
                        },
                        {
                            "requirement_type": "timing_relative_to_treatment",
                            "expected_value": "on or after treatment with trastuzumab deruxtecan (T-DXd)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participant is no longer considered eligible for platinum-based therapy per the investigator's opinion or has progressed less than 180 days after the last dose of platinum therapy.",
            "criterions": [
                {
                    "exact_snippets": "Participant is no longer considered eligible for platinum-based therapy per the investigator's opinion",
                    "criterion": "eligibility for platinum-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": "investigator's opinion"
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed less than 180 days after the last dose of platinum therapy",
                    "criterion": "progression after last dose of platinum therapy",
                    "requirements": [
                        {
                            "requirement_type": "time to progression",
                            "expected_value": {
                                "operator": "<",
                                "value": 180,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Relapse or progression after 1 prior line of an ICI-containing regimen (combination or monotherapy) in the locally advanced/metastatic setting, with a maximum of 2 prior lines. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.",
            "criterions": [
                {
                    "exact_snippets": "Relapse or progression after 1 prior line of an ICI-containing regimen (combination or monotherapy) in the locally advanced/metastatic setting",
                    "criterion": "relapse or progression after ICI-containing regimen in locally advanced/metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "prior lines of ICI-containing regimen",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "treatment setting",
                            "expected_value": "locally advanced/metastatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum of 2 prior lines",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "maximum prior lines",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with actionable target tumor mutation should have been previously treated with targeted therapy",
                    "criterion": "treatment with targeted therapy for actionable target tumor mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence of actionable target tumor mutation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior treatment with targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Disease progression while on or after having received treatment with ≥1 prior line of ICI based therapy. Prior anti-PD-(L)1 therapy in the adjuvant setting may be counted as 1 line if there is recurrence within 12 weeks of the last dose. If the subject had BRAF mutated melanoma or other actionable target tumor mutation, they must have had disease progression on targeted therapy as well.",
            "criterions": [
                {
                    "exact_snippets": "Disease progression while on or after having received treatment with ≥1 prior line of ICI based therapy",
                    "criterion": "disease progression after ICI therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of ICI-based therapy lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior anti-PD-(L)1 therapy in the adjuvant setting may be counted as 1 line if there is recurrence within 12 weeks of the last dose",
                    "criterion": "recurrence after adjuvant anti-PD-(L)1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "recurrence after last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "adjuvant anti-PD-(L)1 therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If the subject had BRAF mutated melanoma or other actionable target tumor mutation, they must have had disease progression on targeted therapy as well",
                    "criterion": "disease progression on targeted therapy for actionable mutations",
                    "requirements": [
                        {
                            "requirement_type": "BRAF mutated melanoma or other actionable target tumor mutation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease progression on targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Inadequate treatment washout period before enrollment as specified in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Inadequate treatment washout period before enrollment",
                    "criterion": "treatment washout period",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Inclusion Criterion for PDAC Participants",
            "criterions": [
                {
                    "exact_snippets": "Additional Inclusion Criterion for PDAC Participants",
                    "criterion": "PDAC participants",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy will count as 1 line of prior systemic therapy if there is documented disease progression during therapy or within 6 months of chemotherapy completion.",
            "criterions": [
                {
                    "exact_snippets": "Prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy will count as 1 line of prior systemic therapy if there is documented disease progression during therapy or within 6 months of chemotherapy completion.",
                    "criterion": "prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented disease progression during therapy or within 6 months of chemotherapy completion",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "during therapy",
                                "within 6 months of chemotherapy completion"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Additional Inclusion Criteria for HCC Participants",
            "criterions": []
        },
        {
            "line": "Common Inclusion Criteria for All Participants",
            "criterions": []
        },
        {
            "line": "Additional Inclusion Criteria for HNSCC Participants",
            "criterions": []
        },
        {
            "line": "Participants who meet any of the following criteria will be disqualified from entering the study:",
            "criterions": []
        },
        {
            "line": "Additional Inclusion Criteria for CRC Participants",
            "criterions": []
        },
        {
            "line": "Additional Inclusion Criteria for OVC Participants",
            "criterions": []
        },
        {
            "line": "Additional Inclusion Criteria for CC Participants",
            "criterions": []
        },
        {
            "line": "Additional Inclusion Criteria for EC Participants",
            "criterions": []
        },
        {
            "line": "Participants must meet all of the following criteria to be included in the study:",
            "criterions": []
        },
        {
            "line": "Additional Inclusion Criteria for UC Participants",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}